Friday, September 19th23.4°C
19716
22924

Biologic drugmaker Amgen's 4Q profit jumps 30 per cent on higher sales, tax benefit, Onyx deal

Amgen Inc.'s fourth-quarter profit jumped 30 per cent mainly due to a tax benefit from prior-year audits, an acquisition and higher sales for nearly all its drugs — much of it from price hikes.

The world's biggest maker of biologic drugs said Tuesday that net income was $1.02 billion, or $1.33 per share, up from $788 million or $1.01 per share, a year earlier.

Excluding one-time items, the maker of osteoporosis drug Prolia said earnings amounted to $1.39 billion, or $1.82 per share. Analysts were expecting $1.69 per share.

Revenue rose 13 per cent to $5.01 billion. Analysts expected $4.81 billion, according to FactSet.

"A large part of the beat was the low tax rate," noted Edward Jones analyst Judson Clark, who has a "Hold" recommendation on Amgen's stock after its big run-up early last year.

In after-hours trading following the release of the results, Amgen shares fell 70 cents to $120, after rising $1.84, or 2.2 per cent, to $120.70 in regular trading.

Sales were led by Neulasta and Neupogen for boosting infection-fighting white blood cells, up 8 per cent to a combined $1.41 billion. Sales of immune disorder drug Enbrel rose 3 per cent to $1.12 billion.

Six other established drugs saw sales increases of 10 per cent or more. Those included Prolia, touted in ads by actress Blythe Danner.

Only Aranesp had lower sales, down 4 per cent to $180 million due to lower demand.

CEO Bob Bradway told analysts on a conference call that sales were "strong in the U.S. and once again, we were one of the few companies growing revenues in Europe."

He added that expanding into new regions is key to Amgen's strategy and that the end of a co-promotion deal with Pfizer Inc. on Enbrel should bring Amgen an extra $800 million this year.

Sales were boosted by Amgen's $9.7 billion purchase of Onyx Pharmaceuticals Inc. on Oct. 1, part of Amgen's strategy to become a major player in the market for pricey cancer drugs. Onyx's Kyprolis, a treatment for the blood cancer multiple myeloma, posted sales of $73 million.

Also Thursday, Amgen said a late-stage patient test of evolocumab, for stubbornly high cholesterol, met the study's two main goals for reducing the absolute level of bad, or LDL, cholesterol and for the average per cent reduction. It was tested along with a statin, the widely used cholesterol drugs that include Lipitor. Amgen plans to disclose details later.

The company, based in Thousand Oaks, Calif., forecast 2014 adjusted earnings per share of $7.90 to $8.20 and revenue of about $19.4 billion. That compares with the average analyst forecast for annual earnings per share of $8.17 on revenue of $19.51 billion.

Clark is concerned growth could slow, amid price hikes fueling much of the higher revenue and what he called a "disappointing" forecast.

For 2013, Amgen earned $5.08 billion, or $6.64 per share, on revenue of $18.68 billion.

___

Linda A. Johnson can be followed at http://twitter.com/LindaJ_onPharma

The Canadian Press


Read more Business News

22980


Recent Trending




Today's Market
S&P TSX15265.35-200.19
S&P CDNX955.06-10.73
DJIA17279.7413.75
Nasdaq4579.789-13.637
S&P 5002010.40-0.96
CDN Dollar0.9126+0.0004
Gold1216.90-10.00
Oil92.45-0.62
Lumber329.00-0.90
Natural Gas3.911-0.064

 
Okanagan Companies
Pacific Safety0.16-0.005
Knighthawk0.01-0.005
QHR Technologies Inc1.37+0.05
Cantex0.05-0.01
Anavex Life Sciences0.223-0.0031
Metalex Ventures0.060.00
Russel Metals35.75-1.26
Copper Mountain Mining2.66-0.02
Colorado Resources0.165-0.01
ReliaBrand Inc0.0249+0.0009
Sunrise Resources Ltd0.02-0.005
Mission Ready Services0.29-0.01

 



21097

FEATURED Property
2080397#2210-3843 Brown Road
2 bedrooms 2 baths
$259,900
more details
image2image2image2
Click here to feature your property
Please wait... loading


Disruptive innovation

Last night I was privileged to be able to speak at the Greater Westside Board of Trade business awards dinner. Photo: ContributedI talked about Innovation and Collaboration which are two very interes...


Executors and their duties

There will be a time when you will need to decide who you should appoint as executor of your Will. As well, there may be a time when you will be asked by someone to act as the executor of his or her W...


Power-save your way to a down payment

Part 1 of 2 Photo: Thinkstock.com1. Move in with your parents or in-laws Explain that you're thinking strategically in moving back home. The quickest way to get into the housing market is to ma...

_








Member of BC Press Council


22814